APA (7th ed.) Citation

MH, M., RA, R., N, L., PF, C., P, P., RC, G., . . . DA, Q. (2025). Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure. HemaSphere, 9(11), e70253. https://doi.org/10.1002/hem3.70253

Chicago Style (17th ed.) Citation

MH, Merrill, et al. "Outcomes of Tafasitamab and Lenalidomide in Large B-cell Lymphoma Based on Prior CD19-directed CAR T Exposure." HemaSphere 9, no. 11 (2025): e70253. https://doi.org/10.1002/hem3.70253.

MLA (9th ed.) Citation

MH, Merrill, et al. "Outcomes of Tafasitamab and Lenalidomide in Large B-cell Lymphoma Based on Prior CD19-directed CAR T Exposure." HemaSphere, vol. 9, no. 11, 2025, p. e70253, https://doi.org/10.1002/hem3.70253.